CA2785567C - Inhibitors of flaviviridae viruses - Google Patents

Inhibitors of flaviviridae viruses Download PDF

Info

Publication number
CA2785567C
CA2785567C CA2785567A CA2785567A CA2785567C CA 2785567 C CA2785567 C CA 2785567C CA 2785567 A CA2785567 A CA 2785567A CA 2785567 A CA2785567 A CA 2785567A CA 2785567 C CA2785567 C CA 2785567C
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
het
another aspect
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2785567A
Other languages
English (en)
French (fr)
Other versions
CA2785567A1 (en
Inventor
Eda Canales
Michael O'neil Hanrahan Clarke
Scott E. Lazerwith
Willard Lew
Philip Anthony Morganelli
William J. Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43538203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2785567(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CA2785567A1 publication Critical patent/CA2785567A1/en
Application granted granted Critical
Publication of CA2785567C publication Critical patent/CA2785567C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2785567A 2010-01-15 2011-01-14 Inhibitors of flaviviridae viruses Active CA2785567C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29557610P 2010-01-15 2010-01-15
US61/295,576 2010-01-15
US35348110P 2010-06-10 2010-06-10
US61/353,481 2010-06-10
PCT/US2011/021335 WO2011088345A1 (en) 2010-01-15 2011-01-14 Inhibitors of flaviviridae viruses

Publications (2)

Publication Number Publication Date
CA2785567A1 CA2785567A1 (en) 2011-07-21
CA2785567C true CA2785567C (en) 2018-03-27

Family

ID=43538203

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2785567A Active CA2785567C (en) 2010-01-15 2011-01-14 Inhibitors of flaviviridae viruses

Country Status (27)

Country Link
US (2) US8513298B2 (enExample)
EP (2) EP2523950B1 (enExample)
JP (2) JP5868872B2 (enExample)
KR (1) KR101727776B1 (enExample)
CN (1) CN102712633B (enExample)
AP (1) AP3576A (enExample)
AR (1) AR080001A1 (enExample)
AU (1) AU2011205744B2 (enExample)
BR (1) BR112012017382A2 (enExample)
CA (1) CA2785567C (enExample)
CL (1) CL2012001960A1 (enExample)
CR (1) CR20120417A (enExample)
EA (1) EA021196B1 (enExample)
EC (1) ECSP12012104A (enExample)
ES (1) ES2626150T3 (enExample)
IL (1) IL220545B (enExample)
MX (1) MX2012008211A (enExample)
NZ (1) NZ600817A (enExample)
PE (1) PE20130281A1 (enExample)
PL (1) PL2523950T3 (enExample)
PT (1) PT2523950T (enExample)
SG (2) SG10201500298PA (enExample)
SI (1) SI2523950T1 (enExample)
TW (1) TWI491609B (enExample)
UY (1) UY33183A (enExample)
WO (1) WO2011088345A1 (enExample)
ZA (1) ZA201205248B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010276441B2 (en) * 2009-07-21 2015-07-02 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
EP2507249B1 (en) 2009-09-09 2015-11-11 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
AU2011205744B2 (en) 2010-01-15 2015-06-25 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
PT2523951E (pt) * 2010-01-15 2015-09-14 Gilead Sciences Inc Inibidores de vírus flaviviridae
WO2012087596A1 (en) * 2010-12-20 2012-06-28 Gilead Sciences, Inc. Combinations for treating hcv
DE102011003295A1 (de) * 2011-01-28 2012-08-02 Kiekert Ag Kraftfahrzeugschloss
EP2734515B1 (en) * 2011-07-13 2015-11-04 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
AU2012308295B2 (en) * 2011-09-16 2017-10-26 Gilead Sciences, Inc. Methods for treating HCV
CN103087052A (zh) * 2011-10-31 2013-05-08 上海壹志医药科技有限公司 噻吩衍生物及其药物用途
CA2875718A1 (en) 2012-06-08 2013-12-12 Selcia Limited Macrocyclic inhibitors of flaviviridae viruses
NZ724503A (en) 2012-06-08 2017-12-22 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN107074904B (zh) 2014-10-23 2022-12-23 深圳华大智造科技股份有限公司 信号约束测序(scs)和用于信号约束测序的核苷酸类似物
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017192599A1 (en) 2016-05-02 2017-11-09 Florida State University Research Foundation, Inc. Treatment of zika virus infections using alpha-glucosidase inhibitors
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
LT3464336T (lt) 2016-06-01 2022-05-10 Athira Pharma, Inc. Junginiai
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
CN108096562B (zh) * 2017-12-25 2021-05-11 武汉百药联科科技有限公司 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途
US12577240B2 (en) 2020-07-11 2026-03-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US743729A (en) * 1903-03-02 1903-11-10 William Clark Kirk Work-support for lathes.
US3533088A (en) * 1967-10-31 1970-10-06 Rca Corp Control circuit for memory
US4714839A (en) * 1986-03-27 1987-12-22 Advanced Micro Devices, Inc. Control circuit for disabling or enabling the provision of redundancy
US4721868A (en) * 1986-09-23 1988-01-26 Advanced Micro Devices, Inc. IC input circuitry programmable for realizing multiple functions from a single input
JPH02146195A (ja) * 1988-11-28 1990-06-05 Nec Corp 半導体記憶装置
JPH03214500A (ja) * 1990-01-18 1991-09-19 Sony Corp メモリ装置
JP2575919B2 (ja) * 1990-03-22 1997-01-29 株式会社東芝 半導体記憶装置の冗長回路
US5959445A (en) * 1995-09-29 1999-09-28 Intel Corporation Static, high-sensitivity, fuse-based storage cell
US5861421A (en) 1995-12-21 1999-01-19 Smithkline Beecham Corporation 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds
US6037799A (en) * 1995-12-29 2000-03-14 Stmicroelectronics, Inc. Circuit and method for selecting a signal
US20050119332A1 (en) * 1998-03-12 2005-06-02 Lone Jeppesen Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
US6175261B1 (en) * 1999-01-07 2001-01-16 Texas Instruments Incorporated Fuse cell for on-chip trimming
US6275063B1 (en) * 1999-08-24 2001-08-14 Micron Technology, Inc. Method and apparatus for limited reprogrammability of fuse options using one-time programmable elements
US6353336B1 (en) * 2000-03-24 2002-03-05 Cypress Semiconductor Corp. Electrical ID method for output driver
US6887877B2 (en) * 2001-06-11 2005-05-03 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
CN101624391A (zh) * 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
KR100481179B1 (ko) * 2002-09-10 2005-04-07 삼성전자주식회사 퓨즈를 구비한 회로 및 이를 이용한 반도체 장치
JP3884374B2 (ja) * 2002-12-06 2007-02-21 株式会社東芝 半導体装置
CN100413861C (zh) * 2002-12-10 2008-08-27 维勒凯姆制药股份有限公司 用于治疗或预防黄病毒感染的化合物
EP1569929B9 (en) 2002-12-10 2011-09-14 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
KR100569585B1 (ko) * 2003-12-05 2006-04-10 주식회사 하이닉스반도체 내부 전원 드라이버 제어 회로
DE10359791A1 (de) * 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
WO2005081954A2 (en) * 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
RU2006138036A (ru) 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
US7569600B2 (en) * 2005-05-13 2009-08-04 Virochem Pharma Inc. Compounds and methods for the treatment of prevention of Flavivirus infections
CN101501215A (zh) 2005-07-07 2009-08-05 阿什洛米克斯控股有限公司 用于诊断内毒素血症的多核苷酸标记基因及它们的表达
GB0602046D0 (en) 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
TW200801022A (en) 2006-02-15 2008-01-01 Sanofi Aventis Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
CN102675279A (zh) * 2006-11-15 2012-09-19 Viro化学制药公司 用于治疗或预防黄病毒属感染的噻吩类似物
WO2008059042A1 (en) * 2006-11-17 2008-05-22 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti viral agents
BRPI0922364A2 (pt) 2008-12-03 2017-08-29 Presidio Pharmaceuticals Inc Composto, composição farmacêutica e uso de um composto
AU2010276441B2 (en) * 2009-07-21 2015-07-02 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
EP2507249B1 (en) * 2009-09-09 2015-11-11 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
MX2012006026A (es) 2009-11-25 2012-08-15 Vertex Pharma Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
AU2011205744B2 (en) * 2010-01-15 2015-06-25 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
PT2523951E (pt) * 2010-01-15 2015-09-14 Gilead Sciences Inc Inibidores de vírus flaviviridae
UY33473A (es) 2010-06-28 2012-01-31 Vertex Pharma Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
EP2734515B1 (en) 2011-07-13 2015-11-04 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses

Also Published As

Publication number Publication date
JP5868872B2 (ja) 2016-02-24
ES2626150T3 (es) 2017-07-24
AU2011205744A1 (en) 2012-07-26
PE20130281A1 (es) 2013-03-08
AU2011205744B2 (en) 2015-06-25
EA201290576A1 (ru) 2013-01-30
CR20120417A (es) 2012-11-30
US20110178129A1 (en) 2011-07-21
CN102712633A (zh) 2012-10-03
NZ600817A (en) 2014-08-29
TW201134822A (en) 2011-10-16
BR112012017382A2 (pt) 2017-12-05
US8513298B2 (en) 2013-08-20
US20130315861A1 (en) 2013-11-28
PL2523950T3 (pl) 2017-09-29
WO2011088345A1 (en) 2011-07-21
SG182475A1 (en) 2012-08-30
IL220545A0 (en) 2012-08-30
SG10201500298PA (en) 2015-03-30
AP2012006414A0 (en) 2012-08-31
TWI491609B (zh) 2015-07-11
UY33183A (es) 2011-08-31
ZA201205248B (en) 2013-03-27
CN102712633B (zh) 2015-07-29
CA2785567A1 (en) 2011-07-21
KR20120101733A (ko) 2012-09-14
SI2523950T1 (sl) 2017-06-30
AR080001A1 (es) 2012-03-07
AP3576A (en) 2016-02-08
EP2523950A1 (en) 2012-11-21
KR101727776B1 (ko) 2017-04-17
PT2523950T (pt) 2017-06-01
CL2012001960A1 (es) 2012-10-26
US9321753B2 (en) 2016-04-26
EA021196B1 (ru) 2015-04-30
EP2523950B1 (en) 2017-03-15
JP2016041732A (ja) 2016-03-31
ECSP12012104A (es) 2012-09-28
JP2013517291A (ja) 2013-05-16
IL220545B (en) 2018-02-28
EP3219713A1 (en) 2017-09-20
MX2012008211A (es) 2012-08-08

Similar Documents

Publication Publication Date Title
CA2785567C (en) Inhibitors of flaviviridae viruses
US8501714B2 (en) Inhibitors of Flaviviridae viruses
US8884030B2 (en) Inhibitors of Flaviviridae viruses
ES2427342T3 (es) Ácidos 5-alquiniltien-2-ilcarboxílicos como inhibidores de virus de los Flaviviridae
CA2840445A1 (en) Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
HK1236521A1 (en) Inhibitors of flaviviridae viruses
AU2013202999A1 (en) Inhibitors of flaviviridae viruses
HK1171444B (en) Inhibitors of flaviviridae viruses
HK1171444A (en) Inhibitors of flaviviridae viruses
HK1170740B (en) Inhibitors of flaviviridae viruses
HK1171443B (en) Inhibitors of flaviviridae viruses

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160106

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241121